Despite
the development of various therapeutic modalities to tackle
cancer, multidrug resistance (MDR) and incomplete destruction of deep
tissue-buried tumors remain as long-standing challenges responsible
for tumor recurrence and low survival rates. In addition to the MDR
and deep tissue photoactivation problems, most primary tumors metastasize
to the lungs and lymph nodes to form secondary tumors. Therefore,
it leaves a great challenge to develop theranostic approaches to combat
both MDR and deep tissue photoactivation problems. Herein, we develop
a versatile plasmonic CuO/Cu2O truncated nanocube-based
theranostic nanomedicine to act as a triple modal near-infrared fluorescence
(NIRF) imaging agent in the biological window II (1000–1500
nm)/photoacoustic imaging (PAI)/T
1-weighted
magnetic resonance (MR) imaging agents, sensitize the formation of
singlet oxygen (1O2) to exert nanomaterial-mediated
photodynamic therapeutic (NIR-II NmPDT), and absorb long NIR light
(i.e., 1550 nm) in the biological window III (1500–1700 nm)
to exert nanomaterial-mediated photothermal therapeutic (NIR-III NmPTT)
effects for the effective destruction of multi-drug-resistant lung
tumors. We found that H69AR lung cancer cells do not create drug resistance
toward plasmonic CuO/Cu2O TNCs-based nanomedicines.